HRP920192B1 - Pharmaceutical composition suitable for influencing the reticuloendothelial system and for treating mucoviscidosis and chronic pain syndromes deriving from degenerative locomotor diseases or accompanying the diseases of tumorous origin - Google Patents

Pharmaceutical composition suitable for influencing the reticuloendothelial system and for treating mucoviscidosis and chronic pain syndromes deriving from degenerative locomotor diseases or accompanying the diseases of tumorous origin

Info

Publication number
HRP920192B1
HRP920192B1 HR920192A HRP920192A HRP920192B1 HR P920192 B1 HRP920192 B1 HR P920192B1 HR 920192 A HR920192 A HR 920192A HR P920192 A HRP920192 A HR P920192A HR P920192 B1 HRP920192 B1 HR P920192B1
Authority
HR
Croatia
Prior art keywords
diseases
influencing
pharmaceutical composition
accompanying
chronic pain
Prior art date
Application number
HR920192A
Other languages
English (en)
Inventor
Joszef Beres
Joszef Beres Jr
Original Assignee
Beres Export Imp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beres Export Imp filed Critical Beres Export Imp
Publication of HRP920192A2 publication Critical patent/HRP920192A2/hr
Publication of HRP920192B1 publication Critical patent/HRP920192B1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/32—Manganese; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/34—Copper; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Percussion Or Vibration Massage (AREA)
  • Catching Or Destruction (AREA)
  • Measurement And Recording Of Electrical Phenomena And Electrical Characteristics Of The Living Body (AREA)
  • Electrotherapy Devices (AREA)
  • Circuits Of Receivers In General (AREA)
  • Steroid Compounds (AREA)
  • Saccharide Compounds (AREA)
HR920192A 1991-07-24 1992-06-26 Pharmaceutical composition suitable for influencing the reticuloendothelial system and for treating mucoviscidosis and chronic pain syndromes deriving from degenerative locomotor diseases or accompanying the diseases of tumorous origin HRP920192B1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
HU912492A HU207799B (en) 1991-07-24 1991-07-24 Process for producing pharmaceutical composition for influencing the reticuloendothelial system, for treating chronic pain symptomes of degenerative locomotor disorders or tumors, and for treating mucoviscidosis

Publications (2)

Publication Number Publication Date
HRP920192A2 HRP920192A2 (hr) 1994-04-30
HRP920192B1 true HRP920192B1 (en) 2000-06-30

Family

ID=10959658

Family Applications (1)

Application Number Title Priority Date Filing Date
HR920192A HRP920192B1 (en) 1991-07-24 1992-06-26 Pharmaceutical composition suitable for influencing the reticuloendothelial system and for treating mucoviscidosis and chronic pain syndromes deriving from degenerative locomotor diseases or accompanying the diseases of tumorous origin

Country Status (18)

Country Link
US (2) US5312629A (sl)
EP (1) EP0524633B1 (sl)
JP (1) JP2673852B2 (sl)
KR (1) KR100234855B1 (sl)
AT (1) ATE178213T1 (sl)
BG (1) BG61250B1 (sl)
CA (1) CA2074639C (sl)
CZ (1) CZ281672B6 (sl)
DE (1) DE69228777T2 (sl)
FI (1) FI923364A (sl)
HR (1) HRP920192B1 (sl)
HU (1) HU207799B (sl)
PL (1) PL169684B1 (sl)
RO (1) RO109505B1 (sl)
RU (1) RU2093160C1 (sl)
SI (1) SI9200155A (sl)
SK (1) SK278944B6 (sl)
YU (1) YU48243B (sl)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5843481A (en) * 1994-01-18 1998-12-01 Mount Sinai Hospital Corporation Treatment of proliferative disorders, metastasaes, and drug resistant tumors with vanadate compounds and derivatives or analogues thereof
US5871779A (en) * 1994-01-18 1999-02-16 Mount Sinai Hospital Corporation Treatment of arthropathies with vanadate compounds or analogues thereof
GB9416768D0 (en) * 1994-08-18 1994-10-12 Nycomed Innovation Ab Compositions
WO1996005867A2 (en) * 1994-08-18 1996-02-29 Nycomed Imaging A/S Compositions
US5863519A (en) * 1994-08-18 1999-01-26 Nycomed Imaging As Composition and method of MRI using both a positive and a negative contrast agent
GB9416767D0 (en) * 1994-08-18 1994-10-12 Nycomed Innovation Ab Compositions
FR2740342B1 (fr) * 1995-10-26 1997-12-19 Oreal Utilisation de sel de lanthanide, de manganese, de lithium, d'etain, de zinc ou d'yttrium, de cobalt, de baryum, de strontium dans des compositions pharmaceutiques
RU2146146C1 (ru) * 1999-05-05 2000-03-10 Дубинина Лариса Васильевна Репаративно-регенеративный препарат, способ его изготовления и лечебного использования по л.в.дубининой
US20030170318A1 (en) * 2000-09-29 2003-09-11 Steiner Gregory Gene Fluoride compositions and uses thereof
US6638431B2 (en) * 2001-05-03 2003-10-28 Mainstream Engineering Corporation Formulation and method for treating wetted surface elements in climate control systems
KR100889994B1 (ko) * 2003-08-14 2009-03-24 한영미 녹반을 함유하는 항암활성을 갖는 조성물
KR20050018250A (ko) * 2003-08-14 2005-02-23 한영주 복합생약 조성물을 함유하는 항암활성을 갖는 조성물
US20060134227A1 (en) * 2004-12-22 2006-06-22 Bortz Jonathan D Compositions including iron
WO2006130027A1 (en) * 2005-05-31 2006-12-07 Santos Ma Joyce Bedelia B Aqueous oral liquid vitamin supplements containing stabilized vitamin c and metal ions
US20090214500A1 (en) * 2005-06-02 2009-08-27 U.S. Borax Inc. Prevention and treatment of osteochondrosis in animals and humans
CN101578051A (zh) * 2006-12-06 2009-11-11 美国硼砂公司 动物饲料组合物
US8008035B2 (en) 2007-01-25 2011-08-30 Roche Diagnostics Operations, Inc. Enhancement of vanadium-containing phosphatase inhibitors
EP1949894B1 (en) * 2007-01-25 2016-06-29 Roche Diagnostics GmbH Enhancement of vanadium-containing phosphatase inhibitors by polyols
US10634385B2 (en) 2009-09-03 2020-04-28 Ademco Inc. Heat balancing system
KR20210025132A (ko) 2012-05-11 2021-03-08 주식회사 젬백스앤카엘 항염증 활성을 갖는 펩티드 및 이를 포함하는 조성물
US10967000B2 (en) 2012-07-11 2021-04-06 Gemvax & Kael Co., Ltd. Cell-penetrating peptide, conjugate comprising same and composition comprising same
CN104508485B (zh) 2013-06-07 2017-01-18 杰姆维克斯&凯尔有限公司 在癌症免疫疗法中有用的生物标记
KR20160039152A (ko) 2013-06-21 2016-04-08 주식회사 젬백스앤카엘 호르몬 분비 조절제, 이를 포함하는 조성물, 및 이를 사용한 호르몬 분비 조절 방법
KR102314231B1 (ko) 2013-12-17 2021-10-19 주식회사 젬백스앤카엘 전립선 암 치료용 조성물
WO2015126265A1 (en) * 2014-02-18 2015-08-27 Santos Joyce Bedelia B Oral liquid vitamin supplements containing zinc and stabilized vitamin c with reduced astringency
EP3130345B9 (en) 2014-04-11 2022-05-04 Gemvax & Kael Co., Ltd. Peptide having fibrosis inhibitory activity and composition containing same
CN106659149B (zh) 2014-04-30 2020-05-19 珍白斯凯尔有限公司 用于器官、组织或细胞移植的组合物、试剂盒和移植方法
KR102413243B1 (ko) 2014-12-23 2022-06-27 주식회사 젬백스앤카엘 안질환 치료 펩티드 및 이를 포함하는 안질환 치료용 조성물
US10835582B2 (en) 2015-02-27 2020-11-17 Gemvax & Kael Co. Ltd. Peptide for preventing hearing loss, and composition comprising same
JP6923453B2 (ja) 2015-07-02 2021-08-18 ジェムバックス アンド カエル カンパニー，リミティド 抗ウイルス活性効能を有するペプチド及びこれを含む組成物
KR20230028596A (ko) 2016-04-07 2023-02-28 김상재 텔로머라제 활성 증가 및 텔로미어 연장 효능을 가지는 펩티드 및 이를 포함하는 조성물

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2022998B (en) * 1978-06-14 1982-09-08 Beres J Phermaceutical composition for the treatment of neoplasticand other diseases
JPS554348A (en) * 1978-06-26 1980-01-12 Peresu Yozefu Drug composition for treating variety of illness by influence to reticuloendotherial tissue and method of treating maligmant tumor with said composition in treating human

Also Published As

Publication number Publication date
RU2093160C1 (ru) 1997-10-20
FI923364A (fi) 1993-01-25
PL295352A1 (en) 1993-02-22
BG61250B1 (bg) 1997-04-30
SI9200155A (en) 1993-03-31
YU81092A (sr) 1996-01-09
EP0524633A3 (en) 1993-07-28
SK232692A3 (en) 1995-06-07
HU207799B (en) 1993-06-28
CA2074639A1 (en) 1993-01-25
YU48243B (sh) 1997-08-22
BG96686A (bg) 1993-12-24
EP0524633B1 (en) 1999-03-31
DE69228777D1 (de) 1999-05-06
CZ232692A3 (en) 1993-02-17
US5405620A (en) 1995-04-11
JP2673852B2 (ja) 1997-11-05
HU912492D0 (en) 1991-12-30
CZ281672B6 (cs) 1996-12-11
DE69228777T2 (de) 1999-10-21
PL169684B1 (pl) 1996-08-30
HRP920192A2 (hr) 1994-04-30
KR930001915A (ko) 1993-02-22
ATE178213T1 (de) 1999-04-15
FI923364A0 (fi) 1992-07-24
KR100234855B1 (ko) 1999-12-15
US5312629A (en) 1994-05-17
EP0524633A2 (en) 1993-01-27
SK278944B6 (sk) 1998-05-06
HUT61475A (en) 1993-01-28
CA2074639C (en) 1996-01-09
RO109505B1 (ro) 1995-03-30
JPH06227992A (ja) 1994-08-16

Similar Documents

Publication Publication Date Title
EP0524633A3 (en) Pharmaceutical composition suitable for influencing the reticuloendothelial system
AU2054097A (en) Polyazamacrocyclofluoromonoalkylphosphonic acids, and their complexes, for use as contrast agents
CA2263379A1 (en) Method for iron delivery to a patient by transfer from dialysate
AU8110098A (en) A process for the preparation of macrocyclic chelants and the chelates thereof with paramagnetic metal ions
AP2002002430A0 (en) Metal-containing compositions, preparations and uses.
CA2020858A1 (en) Water treatment agent and water treatment method for boiler
AU628095B2 (en) Chelants possessing ortho ligating functionality and complexes thereof
ES8303440A1 (es) "procedimiento para la preparacion de acidos oxazafosforin-4-tio-alcansulfonicos".
ES8500226A1 (es) Un procedimiento de preparacion de imino-2-pirrolidinas.
AU657748B2 (en) Improvements in or relating to method of connecting a manganese steel part to another carbon steel part and assembly thus obtained
WO1999039707A8 (en) Metal-thiols as immunomodulating agents
ES8300066A1 (es) Procedimiento para la obtencion de un nuevo antiacido gas- trico
AU2415699A (en) 1,4,7,10-tetraazacyclododecane-1,4-diacetic acid
ES8701185A1 (es) Un procedimiento para preparar un complejo metalico farma- ceuticamente aceptable de un compuesto bis-indolico
AU2170701A (en) Brightening/passivating metal surfaces without hazard from emissions of oxides of nitrogen
EP0805211A3 (en) Process for producing optically active aminopolycarboxylic acid
AU5214900A (en) Pressed products of non-caking salt
ES2044777A1 (es) Procedimiento de obtencion de un quelato de hierro de gran solubilidad.
AU2049995A (en) Tumor affinity peptide, and radioactive diagnostic agent and adioactive therapeutic agent containing the peptide
HUP9801499A2 (hu) Metasztázisgátló gyógyászati készítmény és eljárás ennek előállítására
ES8604492A1 (es) Un procedimiento para producir una sal de nitrilotriacetato
ES8601289A1 (es) Procedimiento para eliminar las capas o manchas de aceite que contaminan las aguas, principalmente las aguas de los mares.
EP0457438A3 (en) Conjugate compounds containing aza-macrocycles, and processes for their preparation
GB1216388A (en) A process for purifying amino acids
FR2646348B1 (sl)

Legal Events

Date Code Title Description
A1OB Publication of a patent application
AIPI Request for the grant of a patent on the basis of a substantive examination of a patent application
B1PR Patent granted
ODRP Renewal fee for the maintenance of a patent

Payment date: 20110623

Year of fee payment: 20

PB20 Patent expired after termination of 20 years

Effective date: 20120627